Company Profile

FLAG Therapeutics Inc
Profile last edited on: 1/9/19      CAGE: 6XQB1      UEI: F1A8MRLKUP37

Business Identifier: Anti-angiogenic/Anti-tubulin (AA/AT) and Folate-target Anti-cancer (FTAC) platforms.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9168 Wooden Road
Raleigh, NC 27617
   (919) 294-6472
Location: Single
Congr. District: 04
County: Wake

Public Profile

FLAG Therapeutics is developing cancer therapeutics using new classes of small molecules having selective dual activity: antiangiogenesis and chemotherapeutic: two investigational product platforms--the Anti-angiogenic/Anti-tubulin (AA/AT) platform and Folate-target Anti-cancer (FTAC) platform.An area of focus is LAG-003, a small molecule which has anti-angiogenic and anti-tubulin properties for the treatment of Glioblastoma brain tumors. FLAG has licensed two classes of small molecules from Duquesne University (Pgh, PA): AA/AT compounds which are both anti-angiogenic and antitubulin; and FTAC compounds, which are cytotoxic but only taken up by a novel receptor that only sits on certain cancer cells.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 2 NIH $1,499,941
Project Title: Development of Novel Targeted Chemotherapeutics for the Treatment Ofmalignant Pleural Mesothelioma

Key People / Management

  Frank Sorgi -- Founder, President and CEO

  Gregory J Divis -- Chief Business Officer

  Jim Shamp -- Director of Public Relations

Company News

There are no news available.